Compare Nasdaq Inc (NDAQ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Novartis AG — how do they compare? Nasdaq Inc trades at $93.58 (market cap $51.63B), while Novartis AG trades at $143.31 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5.2× Nasdaq Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Novartis AG for 82 Days on average.
| NDAQ | NVS | |
|---|---|---|
Market Cap | $51.63B | $268.57B |
Volume | 2,668,175 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $100.98 | $168.62 |
52-Week Low | $76.85 | $121.80 |
Typical Hold Time | 125 Days | 82 Days |
Enterprise Value | $58.09B | $309.89B |
Dividend Yield | 1.26% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
